Mahmoud Jaber

Dr. Mahmoud Jaber


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
AAAdil A Abalkhail
Adil A Abalkhail
MIMahmudul Hassan Al Imam
Mahmudul Hassan Al Imam
YEYousif Mohammed Elmosaad
Yousif Mohammed Elmosaad
MJMahmoud Jaber
Mahmoud Jaber
KHKhaled Al Hosis
Khaled Al Hosis
IMIlias Mahmud
Ilias Mahmud
Hospital-acquired infections (HAIs) contribute to increased length of hospital stay, higher mortality and higher health-care costs. Prevention and control of HAIs is a critical public health concern. This study assessed the knowledge, attitude, and practice (KAP) of standard infection control precautions among health-care workers (HCWs) in Qassim, Saudi Arabia. A cross-sectional online survey among HCWs was conducted using a structured questionnaire. Predictors of KAP were investigated using multivariate logistic regression analyses and independent sample t-tests. A total of 213 HCWs participated in the survey. The prevalence of good (≥80% correct response) knowledge, attitude, and practice were 67.6%, 61.5%, and 73.2%, respectively. The predictors of good knowledge included the age of the HCWs (>34 years) (adjusted odds ratio: 30.5, p < 0.001), and training (13.3, p < 0.001). More than 6 years of work experience was a significant predictor of having a positive attitude (5.5, p < 0.001). While the predictors of good practice were having >6 years of experience (2.9, p < 0.01), previous exposure to HAIs (2.5, p < 0.05), and training (3.5, p < 0.01). However, being female (0.22, p < 0.001) and older (>34 years) (0.34, p < 0.01) were negatively associated with knowledge. Results indicate that arranging training for HCWs might be useful in improving their knowledge of standard infection control precautions and is also expected to facilitate positive attitude and practice.

4 January 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
AEAyman Elbehiry
Ayman Elbehiry
EMEman Marzouk
Eman Marzouk
HAHusam Mohamed Edrees Ismail Abdelrazek
Husam Mohamed Edrees Ismail Abdelrazek
MIMai Ibrahem
Mai Ibrahem
SASafiyah Hashim Alzahrani
Safiyah Hashim Alzahrani
Akram Abu-OkailAkram Abu-Okail
Akram Abu-Okail
Pseudomonas aeruginosa (P. aeruginosa) forms biofilms that are difficult to eliminate. The matrix protects the cells, efflux pumps reduce intracellular drug levels, and dormant subpopulations survive treatment. Routine minimum inhibitory concentration (MIC) testing does not account for these features, which helps explain why infections often continue even when therapy appears appropriate. This review describes how quorum-sensing (QS) and cyclic di-guanosine monophosphate (c-di-GMP) regulate matrix production, efflux activity, and dormancy within P. aeruginosa biofilms. Important matrix components, including Psl, Pel, alginate, and extracellular DNA, slow the movement of antimicrobial agents. Regulatory proteins such as sagS and brlR increase the activity of the MexAB-OprM and MexEF-OprN efflux systems, further reducing intracellular drug concentrations. Oxygen and nutrient limitation promote persister cells and viable but nonculturable cells, with both having the ability to survive antibiotic levels that would normally be lethal. These defenses explain the gap between MIC values and biofilm-specific measurements, such as the minimum biofilm inhibitory concentration and the minimum biofilm eradication concentration. This review also summarizes emerging antibiofilm strategies. These include QS inhibitors, compounds that lower c-di-GMP, such as nitric oxide donors, nanoparticles, depolymerases, bacteriophages, and therapies that are directed at host targets. Modern diagnostic tools, such as confocal laser scanning microscopy, optical coherence tomography, and Raman spectroscopy, improve detection and guide treatment planning. A staged therapeutic approach is presented that begins with the dispersal or loosening of the matrix, continues with targeted antibiotics, and concludes with support for immune clearance. Viewing these strategies within a One Health framework highlights the role of biofilms in clinical disease and in environmental reservoirs and supports more effective surveillance and prevention.

21 July 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
IMIlias Mahmud
Ilias Mahmud
MIMahmudul Hassan Al Imam
Mahmudul Hassan Al Imam
Divya VinnakotaDivya Vinnakota
Divya Vinnakota
Khalid A. KheirallahKhalid A. Kheirallah
Khalid A. Kheirallah
MJMahmoud Jaber
Mahmoud Jaber
Russell KabirRussell Kabir
Russell Kabir
Objective: This study assessed the intention and predictors of accepting the corona virus disease 2019 (COVID-19) vaccine in Jordan. Method: A national-level online survey was conducted among adults (≥18 years) in Jordan between June and September 2021. Descriptive analyses were performed to report vaccination intent. In addition, bivariate and multivariate logistic regression analyses were done to evaluate the association between vaccination intent and its predictors. Results: A total of 2307 adults participated. Most of them (83.7%) expressed an intention to receive a COVID-19 vaccine. Their vaccination intention was significantly (p < 0.001) associated with male gender (aOR: 2.6), residence in the Amman region (aOR: 51.8), and no history of COVID-19 infection (aOR: 6.0). In contrast, individuals aged 50-64 years (aOR: 0.2, p < 0.001), Jordanians (aOR: 0.7, p = 0.038), and those with an occupation designated as “other” (unemployed, general workers, housewives) (aOR: 0.2, p < 0.001) were less likely to have a positive vaccination intent. Among the health belief model constructs, perceived future (aOR: 2.8) and present (aOR: 5.0) susceptibility to COVID-19 infection; severity of complications (aOR: 9.9); and benefits (aOR: 100.8) were significantly (p < 0.001) associated with a higher likelihood of having a vaccination intent. On the other hand, individuals who are concerned about the efficacy (aOR: 0.2) and side effects (aOR: 0.2) of the vaccine were less likely to have a positive vaccination intent (p < 0.001). Conclusion: Despite having high rates of intention to receive a COVID-19 vaccine, Jordanians, older adults and housewives, general workers and unemployed individuals were less likely to be vaccinated. These findings highlight that need-based public health campaigns are necessary to ensure maximum COVID-19 vaccination uptake in Jordan.

22 September 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
EMEman Marzouk
Eman Marzouk
MJMahmoud Jaber
Mahmoud Jaber
Antimicrobial therapy may fail even when an agent is intrinsically active if effective drug exposure is not achieved at the site of infection at the appropriate time. This challenge is particularly important in biofilm-associated infections and infections caused by drug-resistant pathogens, where biological barriers, spatial heterogeneity, and changing microbial states can limit treatment effectiveness. This narrative review examines advanced antimicrobial delivery from a problem-oriented perspective, focusing on the therapeutic challenges that delivery systems are designed to address. It explores how antimicrobial exposure can be aligned with the location, biological state, and changing course of infection. The review examines the biological and pharmacological barriers that restrict antimicrobial activity and discusses strategies designed to improve drug access, retention, release, and local activity. Localized delivery, responsive and externally triggered systems, controlled and sequential delivery, and multimodal therapy are considered as implementation strategies within a common spatiotemporal framework. Particular attention is given to the relationship between formulation design, local drug exposure, biological response, and therapeutic outcome. The review further examines the factors that determine whether a technically promising system has a realistic clinical role, including safety, reproducibility, manufacturability, model relevance, and demonstrable benefits over simpler approaches. Future priorities are considered from a clinically defined perspective. Overall, the review argues that the value of advanced antimicrobial delivery lies not in carrier complexity alone, but in its capacity to provide a measurable and reproducible therapeutic advantage for a clearly defined infection setting.

23 April 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
AAAbdulaziz Almuzaini
Abdulaziz Almuzaini
MJMahmoud Jaber
Mahmoud Jaber
AEAyman Elbehiry
Ayman Elbehiry
Methicillin-resistant Staphylococcus aureus (MRSA) is a major clinical problem due to its resistance, virulence, and biofilm formation, which diminish antibiotic efficacy. This review explores natural products and antimicrobial nanoparticles (NPs) as alternative and combined strategies for controlling MRSA. Natural compounds, such as plant metabolites, essential oils, antimicrobial peptides, and fungal products, act by disrupting membranes, interfering with cellular processes, and limiting biofilm formation. Antimicrobial NPs, especially metal and metal oxide materials, act through membrane damage, oxidative stress, and metal ion release, enabling activity against resistant bacteria and improving biofilm penetration. Combining natural products with NPs increases stability, delivery, and local activity, enhances antibacterial effects, and reduces effective doses. Green synthesis enables direct integration of bioactive compounds, while nano-delivery platforms optimize solubility and controlled release. Nanotechnology-based applications such as wound dressings, nanocarriers, and multifunctional platforms support localized and sustained treatment and promote tissue repair. Despite these advances, clinical use is still constrained by safety concerns, variability in NP properties, and the lack of standardized evaluation and regulatory frameworks. Overall, combining natural products with antimicrobial NPs offers a practical strategy to augment MRSA treatment, but further progress depends on consistent design, robust safety evaluation, and clinical translation.